The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Open accessAbstract
BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. METHODS: We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients). Secondary end points included the incidences of nonvertebral and hip fracture at the time of the primary analysis. Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures were adjudicated. RESULTS: Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P<0.001). The risk of nonvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 of 2047 patients [10.6%]; P=0.04), and the risk of hip fracture was lower by 38% (41 of 2046 patients [2.0%] vs. 66 of 2047 patients [3.2%]; P=0.02). Overall adverse events and serious adverse events were balanced between the two groups. During year 1, positively adjudicated serious cardiovascular adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed. CONCLUSIONS: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone. (Funded by Amgen and others; ARCH ClinicalTrials.gov number, NCT01631214 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, major cardiac events were observed in the ARCH study, while headaches, arthralgia, and injection site reactions were also observed [89,90].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As of 2021, it has reached Phase III trials, which have shown an increase in bone mineral density and a decrease in vertebral and hip fractures.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ARCH study showed a 48% lower risk of new vertebral fractures in the group that received romosozumab and alendronate than in the alendronate-only group [89].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationRomosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citationBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Cited by
Sorted by citations
Items 601–700 of 1,000
McClung, M. R., Betah, D., Deignan, C., Shi, Y., Timoshanko, J., & Cosman, F. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.06.011 · Cited by 14
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment
Iolascon, G., Liguori, S., Paoletta, M., Toro, G., & Moretti, A. (2023) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x231197094 · Cited by 14
A contemporary therapeutic approach to bone disease in beta-thalassemia - a review
Stefanopoulos, D., Παπαϊωάννου, Ν., Papavassiliou, A. G., Mastorakos, G. P., Vryonidou, A., Michou, A., Dontas, I. A., Lyritis, G. P., Kassi, E. N., & Tournis, S. (2018) · Journal of Frailty Sarcopenia and Falls · doi:10.22540/jfsf-03-013 · Cited by 14
Ramchand, S. K., & Seeman, E. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_354 · Cited by 16
Toro, R. D., Cavallari, I., Tramontana, F., Park, K., Strollo, R., Valente, L., Pascalis, M. D., Grigioni, F., Pozzilli, P., Buzzetti, R., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02736-8 · Cited by 14
Zoulakis, M., Johansson, H., Harvey, N. C., Axelsson, K. F., Litsne, H., Johansson, L., Schini, M., Vandenput, L., McCloskey, E. V., Kanis, J. А., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07588-w · Cited by 13
Self-citationManagement of postmenopausal osteoporosis
Reid, I. R., & Bolland, M. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag006 · Cited by 13
Regulation of bone mass in endocrine diseases including diabetes
Higham, C., & Abrahamsen, B. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101614 · Cited by 13
Cho, E., Che, X., Ang, M. J., Cheon, S., Lee, J., Kim, K. S., Lee, C. H., Lee, S.-Y., Yang, H., Moon, C., et al. (2023) · eLife · doi:10.7554/elife.80122 · Cited by 13
Alonso, N., Albagha, O., Azfer, A., Larraz‐Prieto, B., Berg, K. M., Riches, P. L., Ostanek, B., Kocjan, T., Marc, J., Langdahl, B. L., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223618 · Cited by 13
All the might of the osteocyte: emerging roles in chronic kidney disease
Albrecht, L. V., Pereira, R. C., & Salusky, I. B. (2023) · Kidney International · doi:10.1016/j.kint.2023.08.009 · Cited by 13
Sclerostin, Osteocytes, and Wnt Signaling in Pediatric Renal Osteodystrophy
Laster, M. L., Pereira, R. C., Noche, K. J., Gales, B., Salusky, I. B., & Albrecht, L. V. (2023) · Nutrients · doi:10.3390/nu15194127 · Cited by 14
Position Statement: Postmenopausal Osteoporosis Treatment Strategies in Korea
Park, S. Y., Kim, S. H., Lee, Y., Shin, J., Ha, Y., & Chung, H. Y. (2023) · Journal of Bone Metabolism · doi:10.11005/jbm.2023.30.4.289 · Cited by 13
Latest on Anabolic Agents for Osteoporosis Treatment
di Filippo, L., & Rosen, C. J. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.08.003 · Cited by 13
Mok, C. C., Chan, K. L., Tse, S. M., Chen, S. P. L., Tan, K. C. B., & Ma, W. H. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20017 · Cited by 14
Khan, M. A., Khan, M. A., Siddiqui, S., Misra, A., Yadav, K., Srivastava, A., Trivedi, A., Husain, I., & Ahmad, R. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106740 · Cited by 13
Once-weekly teriparatide reduces serum sclerostin levels in postmenopausal women with osteoprosis
Ikeda, T., Kaji, H., Tamura, Y., & Akagi, M. (2018) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2018.10.028 · Cited by 13
Javaheri, B., Herbert, E., Hopkinson, M., Aljazzar, A., & Pitsillides, A. A. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.12.007 · Cited by 13
Maillard, S., Sicard, L., Andrique, C., Torrens, C., Lesieur, J., Baroukh, B., Coradin, T., Poliard, A., Slimani, L., & Chaussain, C. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.11.046 · Cited by 13
Postmenopausal osteoporosis: risk evaluation and treatment options
Bonaccorsi, G., Rizzati, M., Salani, L., & Giganti, M. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.21.04896-x · Cited by 16
What’s New in Osteoporosis and Fragility Fractures
Hansen, D. G., Tutaworn, T., & Lane, J. M. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.22.00530 · Cited by 13
Conditional Loss of Nmp4 in Mesenchymal Stem Progenitor Cells Enhances PTH-Induced Bone Formation
Atkinson, E. G., Adaway, M., Horan, D. J., Korff, C., Klunk, A. J., Orr, A. L., Ratz, K., Bellido, T., Plotkin, L. I., Robling, A. G., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4732 · Cited by 13
Tratamiento secuencial en osteoporosis. Nuevas tendencias
Casado, E., & Neyro, J. L. (2021) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2021000400002 · Cited by 13
Denosumab as a Pharmacological Countermeasure Against Osteopenia in Long Duration Spaceflight
Rengel, A., Tran, V., & Toh, L. S. (2023) · Aerospace Medicine and Human Performance · doi:10.3357/amhp.6053.2023 · Cited by 13
The Sequential Therapy in Osteoporosis
Sauhta, R., Makkar, D., & Siwach, P. S. (2023) · Indian Journal of Orthopaedics · doi:10.1007/s43465-023-01067-2 · Cited by 13
Park, D., Kim, S. E., Shin, H. K., Seo, J., Joo, J. K., Kim, C., Lee, S. H., & Park, J. H. (2023) · Neurospine · doi:10.14245/ns.2347030.515 · Cited by 13
Lewiecki, E. M., Bilezikian, J. P., Kagan, R., Krakow, D., McClung, M. R., Miller, P. D., Rush, E. T., Shuhart, C., Watts, N. B., & Yu, E. W.-Y. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.09.006 · Cited by 13
Economic implications of osteoporotic fractures in postmenopausal women
Patel, J. (2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88549 · Cited by 13
Modern Strategies for Osteoporosis Therapy: Current Status and Prospects for Targeted Intervention
Omelchenko, V. O., Koval, V., Slazhneva, N., Bondarenko, N. A., Shatunova, E. A., Vorobyeva, M., & Korolev, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211092 · Cited by 14
Yang, D., Tan, J., Long, Y., Huang, K., Han, W., Wang, M., Zhu, S., Zeng, S., & Yi, W. (2023) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02342-w · Cited by 12
The role of sclerostin in lipid and glucose metabolism disorders
Jiang, H., Li, D., Han, Y., Li, N., Tao, X., Liu, J., Zhang, Z., Yu, Y., Wang, L., Yu, S., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115694 · Cited by 12
Henning, P., Kassem, A., Westerlund, A., Lundberg, P., Engdahl, C., Lionikaite, V., Wikström, P., Wu, J., Li, L., Lindholm, C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383113 · Cited by 12
Update on fracture risk assessment in osteoporosis
McCloskey, E. V., Tan, A. T. H., & Schini, M. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000871 · Cited by 12
Lan, Z., Lin, X., Xue, D., Yang, Y., Saad, M., & Jin, Q. (2024) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000003204 · Cited by 12
Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics
Gubu, A., Zhang, G., Jing, N., & Ma, Y. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01293 · Cited by 12
Zhong, Y., Dai, W., Yin, L., Wu, G., & Wang, X. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf003 · Cited by 12
Wells, G. A., Hsieh, S., Peterson, J., Zheng, C., Kelly, S., Shea, B., & Tugwell, P. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001155.pub3 · Cited by 13
Current and Emerging Treatment of Osteoporosis
Tafaro, L., & Napoli, N. (2020) · Practical issues in geriatrics · doi:10.1007/978-3-030-48126-1_15 · Cited by 12
Reid, I. R., Horne, A. M., Mihov, B., Stewart, A., Bolland, M. J., Bastin, S., & Gamble, G. D. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4167 · Cited by 12
Fuji, S., Byrne, M. T., Nagler, A., Mohty, M., & Savani, B. N. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01205-6 · Cited by 12
The Impact of COVID-19 on the Optimal Management of Osteoporosis
Kong, S. H., Hwang, B. K., & Yoon, B. (2021) · Journal of Bone Metabolism · doi:10.11005/jbm.2021.28.2.115 · Cited by 12
Effects of sclerostin antibody on bone healing
Mihara, A., Yukata, K., Seki, T., Iwanaga, R., Nishida, N., Fujii, K., Nagao, Y., & Sakai, T. (2021) · World Journal of Orthopedics · doi:10.5312/wjo.v12.i9.651 · Cited by 12
Biochemical markers of bone turnover in osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00065-4 · Cited by 14
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis
Shen, J., Ke, Z., Dong, S., Lv, M., Yuan, Y., Song, L., Wu, K., Xu, K., & Hu, Y. (2022) · Medical Science Monitor · doi:10.12659/msm.935491 · Cited by 12
Goeree, R. A., Burke, N., Jobin, M., Brown, J. P., Lawrence, D., Stollenwerk, B., Willems, D., & Johnson, B. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01106-9 · Cited by 12
Kanis, J. А., Johansson, H., Harvey, N. C., Gudnason, V. G., Sigurðsson, G., Siggeirsdóttir, K., Lorentzon, M., Liu, E., Vandenput, L., & McCloskey, E. V. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06550-4 · Cited by 13
Self-citationSilva, B. C. C., Madeira, M., d’Alva, C. B., Maeda, S. S., de Holanda, N. C. P., Ohe, M. N., Szejnfeld, V. L., Zerbini, C. A. F., de Paula, F. J. A., & Bandeira, F. A. F. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000522 · Cited by 12
Al-Toma, A. A., Herman, A., Lems, W. F., & Mulder, C. J. J. (2022) · Nutrients · doi:10.3390/nu14214554 · Cited by 13
Prevention of fractures in patients with osteoporosis
Ferrari, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32167-0 · Cited by 12
Bădescu, M. C., Rezuş, E., Ciocoiu, M., Bădulescu, O. V., Butnariu, L. I., Popescu, D., Bratoiu, I., & Rezuș, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020640 · Cited by 12
Chen, J., Yuan, X., Li, Z., Bahat, D. J., & Helms, J. A. (2020) · Dental Materials · doi:10.1016/j.dental.2020.06.003 · Cited by 12
Wei, F., Hughes, M., Omer, M., Ngo, C., Pugazhendhi, A. S., Kolanthai, E., Aceto, M., Ghattas, Y. S., Razavi, M., Kean, T. J., et al. (2024) · Advanced Science · doi:10.1002/advs.202308698 · Cited by 11
Ueno, M., Tajima, Y., Ito, S., Tsuji, M., Toriumi, E., Yoshii, A., Otake, N., & Tanaka, H. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01374-7 · Cited by 11
Update on Atypical Femoral Fractures
Anderson, P. A., Kates, S. L., & Watts, N. B. (2024) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.23.01439 · Cited by 11
Sawada, Y., Takahashi, S., Yasuda, H., Terakawa, M., Konishi, S., Kato, M., Toyoda, H., Suzuki, A., Tamai, K., Iwamae, M., et al. (2024) · The Spine Journal · doi:10.1016/j.spinee.2024.12.021 · Cited by 11
Assessment of fracture risk with FRAX and FRAXplus
Tan, A. T. H., Johansson, H., Harvey, N. C., Lorentzon, M., Kanis, J. А., McCloskey, E. V., & Schini, M. (2024) · Gaceta Médica de México · doi:10.24875/gmm.24000107 · Cited by 11
Self-citationFerrari, S., Betah, D., Feldman, R. G., Langdahl, B. L., Oates, M. K., Timoshanko, J., Wang, Z., & Dhaliwal, R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae862 · Cited by 11
Treatment Considerations for Severe Osteoporosis in Older Adults
See, H., Gowling, E., Boswell, E., Aggarwal, P., King, K., Smith, N., Lim, S. E. R., Baxter, M. A., & Patel, H. P. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01205-5 · Cited by 11
Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formation
Wang, L., Tao, X., Jiang, H., Ding, S., Zhang, N., Yang, X., Wang, S., Zhang, Y., Li, N., Li, H., et al. (2026) · Bone Research · doi:10.1038/s41413-026-00511-x · Cited by 11
Wang, Z., Ishihara, Y., Ishikawa, T., Hoshijima, M., Odagaki, N., Hlaing, E. E., & Kamioka, H. (2018) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0963-7 · Cited by 11
Lee, C.-C., Hung, C., Chen, C., Hsu, Y., Huang, Y.-P., Huang, T., & Lee, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158320 · Cited by 11
Myeloma Bone Disease: The Osteoblast in the Spotlight
Andrews, R. E., Brown, J. E., Lawson, M. A., & Chantry, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173973 · Cited by 11
Kobayakawa, T., Miyazaki, A., Takahashi, J. A., & Nakamura, Y. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.02.002 · Cited by 11
Paracrine and endocrine functions of osteocytes
Michigami, T. (2022) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2022-0053 · Cited by 13
Antisclerostin Effect on Osseointegration and Bone Remodeling
Couto, B. A. D. A., Fernandes, J. C. H., Saavedra-Silva, M., Roca, H., CASTILHO, R. M., & Fernandes, G. V. O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041294 · Cited by 13
Schmidmaier, R., Hadji, P., Kern, P., Drey, M., Jakob, F. J., & Thomasius, F. E. (2023) · Osteologie/Osteology · doi:10.1055/a-2034-6086 · Cited by 11
Romosozumab-associated medication-related osteonecrosis of the jaw
Palla, B. L., Anderson, J., Miloro, M., Moles, S. L., & Callahan, N. F. (2023) · Oral and Maxillofacial Surgery Cases · doi:10.1016/j.omsc.2023.100318 · Cited by 11
Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis
Zhao, N., Wei, W., Xu, Y., Li, D., Yin, B., & Gu, W. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0759 · Cited by 13
van den Bergh, J. P., Geusens, P., Appelman‐Dijkstra, N. M., van den Broek, H. J. G., Elders, P. J. M., de Klerk, G., van Oostwaard, M. M., Willems, H. C., Zillikens, M. C., & Lems, W. F. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01378-3 · Cited by 11
Krikelis, M. I., Gazi, S., Trovas, G., Makris, K., Chronopoulos, E., & Tournis, S. (2024) · Joint Bone Spine · doi:10.1016/j.jbspin.2024.105754 · Cited by 11
The Crucial Role of the WNT System in Bone Remodelling
Grigorie, D. (2018) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2018.90 · Cited by 11
Sclerostin and its role as a bone modifying agent in periodontal disease
Ashifa, N., Viswanathan, K., Sundaram, R., & Srinivasan, S. (2021) · Journal of Oral Biosciences · doi:10.1016/j.job.2021.04.002 · Cited by 12
Albert, S. G., & Wood, E. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.06.015 · Cited by 11
Pharmacologic Interventions for Fracture Risk Reduction in the Oldest Old: What Is the Evidence?
Sfeir, J. G., & Pignolo, R. J. (2021) · JBMR Plus · doi:10.1002/jbm4.10538 · Cited by 11
Khalid, S., Pineda‐Moncusí, M., Elhussein, L., Delmestri, A., Ernst, M., Smith, C., Libanati, C. R., Tóth, E., Javaid, M. K., Cooper, C. C., et al. (2021) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4414 · Cited by 11
The antiresoptive effects of recombinant Lingzhi-8 protein against retinoic acid-induced osteopenia
Ruan, L., Jiang, N., Guo, F., Xu, H. J., Zhang, J., & Sun, J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172669 · Cited by 11
Update on Approved Osteoporosis Therapies Including Combination and Sequential Use of Agents
Saul, D., & Drake, M. T. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.010 · Cited by 11
McCloskey, E. V., Chotiyarnwong, P., Harvey, N. C., Lorentzon, M., Kanis, J. A., Prieto‐Alhambra, D., Abrahamsen, B., Adachi, J. D., Borgström, F., Bruyère, O., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06419-6 · Cited by 11
Self-citationSclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
Xiaohui, T., Wang, L., Yang, X., Jiang, H., Zhang, N., Zhang, H., Li, D., Li, X., Zhang, Y., Wang, S., et al. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.05.004 · Cited by 10
“However, the severe CVEs found in phase III clinical trials limited the clinical usage of romosozumab [33,34].”
BackgroundHattori, K., & Kanayama, Y. (2024) · Modern Rheumatology · doi:10.1093/mr/roae008 · Cited by 10
Chermside‐Scabbo, C. J., Shuster, J. T., Erdmann-Gilmore, P., Tycksen, E., Zhang, Q., Townsend, R. R., & Silva, M. J. (2024) · Aging · doi:10.18632/aging.206131 · Cited by 11
Verifying the effectiveness of romosozumab re-administration on bone mineral density
Kobayakawa, T., & Nakamura, Y. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae196 · Cited by 10
Michaëlsson, K., Zheng, R., Baron, J. A., Fall, T., Wolk, A., Lind, L., Höijer, J., Brunius, C. F., Lemming, E. W., Titova, O. E., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105580 · Cited by 10
Kövér, Z., Gajdács, M., Polgár, B., Szabó, D., & Urbán, E. Z. (2025) · Antibiotics · doi:10.3390/antibiotics14020203 · Cited by 10
Akbar, A., Zaheer, A., Kharal, M. M., Komel, A., Khan, M. H., Ahsan, A., & Singh, A. K. (2025) · Medicine · doi:10.1097/md.0000000000041605 · Cited by 10
Viridicatol from the Deep‐Sea‐Derived Fungus Alleviates Bone Loss by Targeting the Wnt/SHN3 Pathway
Xie, C., Ye, S., Yue, Y., Shi, B., Xu, J., Li, L., Zou, Z., Greenblatt, M. B., Li, N., Yang, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202416140 · Cited by 10
Chao, C., Hou, Y., Liao, M.-T., Tsai, K., Hung, K.-C., Shih, L., & Lu, K. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2530162 · Cited by 10
An, Z., Wu, B., Mao, W., & Wu, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1638629 · Cited by 10
Maruyama, H., Iwasa, E., Watanabe, S., Hasegawa, T., Kajiyama, K., & Tanaka, T. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70142 · Cited by 10
Use of Osteobiologics for Fracture Management: The When, What, and How
Marmor, M. T., Matz, J., McClellan, R. T., Medam, R., & Miclau, T. (2021) · Injury · doi:10.1016/j.injury.2021.01.030 · Cited by 10
Park, J. J., & Wong, C. (2022) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2022.151276 · Cited by 10
Sclerostin ablation prevents aortic valve stenosis in mice
Joll, J. E., Riley, L. A., Bersi, M. R., Nyman, J. S., & Merryman, W. D. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00355.2022 · Cited by 10
The role of vitamin D on rotator cuff tear with osteoporosis
Liu, G., Li, W., Zhang, L., Chao Hui, Z. H. O. U., & Cong, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1017835 · Cited by 10
Prediabetes and Fracture Risk Among Midlife Women in the Study of Women’s Health Across the Nation
Shieh, A., Greendale, G. A., Cauley, J. A., Karvonen-Gutierrez, C. A., & Karlamangla, A. S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.14835 · Cited by 10
di Filippo, L., Ulivieri, F. M., Nuti, R., & Giustina, A. (2023) · Endocrine · doi:10.1007/s12020-023-03551-z · Cited by 11
Vilaça, T., & Eastell, R. (2023) · JBMR Plus · doi:10.1002/jbm4.10838 · Cited by 10
Pathogenesis, assessment, and management of bone loss in axial spondyloarthritis
Nakamura, A., & Towheed, T. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152345 · Cited by 11
Efficacy of Osteoporosis Medications in Patients with Type 2 Diabetes
Vilaça, T., & Eastell, R. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00833-3 · Cited by 10
Liu, W., Nicol, L. E., & ORWOLL, E. S. (2024) · Calcified Tissue International · doi:10.1007/s00223-024-01188-2 · Cited by 10
Seki, K., Nagasaki, M., Yoshino, T., Yano, M., Kawamoto, A., & Shimizu, O. (2024) · Diagnostics · doi:10.3390/diagnostics14101009 · Cited by 10
Metadata
- Authors
- Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A.
- Affiliations
- Inserm (FR)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-12
- Volume
- 377
- Issue
- 15
- Pages
- 1417-1427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2754720807
- Cited by
- 1,544
- References
- 31
- Citations by year
- 2026: 204 · 2025: 216 · 2024: 210 · 2023: 148 · 2022: 179 · 2021: 172 · 2020: 185 · 2019: 114 · 2018: 94 · 2017: 19
- FWCI
- 123.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Teva Pharmaceutical Industries
- Radius Health
- Medac
- Chugai Pharmaceutical
- Amgen Canada
- UCB Pharma
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- romosozumab, alendronate, osteoporosis, fracture prevention, sclerostin inhibition, postmenopausal women, vertebral fractures, hip fracture, non-vertebral fractures, bisphosphonates, cardiovascular adverse events, osteonecrosis of the jaw, atypical femoral fractures, bone formation, bone resorption, fragility fractures, open-label extension
- MeSH terms
- Aged, Antibodies, Monoclonal, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Least-Squares Analysis, Spinal Fractures, Bone Remodeling, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
